Biopharmaceutical company GSK plc (LSE/NYSE: GSK) announced on Wednesday that the European Commission has approved a fully liquid version of Menveo, its meningococcal Group A, C, W-135, and Y conjugate vaccine (MenACWY).
This single-vial formulation, which eliminates the need for reconstitution, simplifies immunisation against invasive meningococcal disease (IMD) and is approved for individuals aged two years and older.
The approval follows two Phase IIb trials demonstrating comparable immunogenicity, tolerability and safety to the existing lyophilised/liquid version. This new presentation supports efficient vaccination workflows for a disease known for its severe, life-threatening complications. IMD remains a critical global health concern, with high mortality rates and significant long-term effects for survivors.
The original lyophilised Menveo formulation, approved in 2010, remains available. Menveo is authorised in over 60 countries and has delivered over 82 million doses globally, with more than 6 million distributed in Europe since 2017.
hVIVO completes pilot study for hMPV challenge model
Merck's Gardasil approved for males in China
Brii Bio acquires BRII-179 IP rights
Valneva and Serum Institute of India partner to expand chikungunya vaccine access in Asia
SK bioscience begins clinical trials for mRNA Japanese encephalitis vaccine
Sanofi's combination vaccine candidates for flu and COVID-19 get Fast Track Designation
hVIVO secures GBP11.5m RSV contract
Novavax sells Czech manufacturing site to Novo Nordisk for USD200m
Valneva reports strong, long-lasting immunity from single-dose chikungunya vaccine